Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesSmall but powerful: Short peptide hormones and their role in autoimmune inflammation
Journal of Neuroimmunology, 09/15/09
Lühder F et al. – Inhibitors of angiotensin converting enzyme and antagonists of the angiotensin 1 receptors are used in the treatment of hypertension, kidney disease or stroke by millions of people worldwide. These inexpensive and safe pharmaceuticals may also represent an interesting and innovative approach for the (combination) treatment of autoimmune diseases like multiple sclerosis.
Related Articles
Innate inflammation and resolution in acute gout
Immunology & Cell Biology, 11/30/09
Relevance Score: 64%
Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome
Immunology & Cell Biology, 11/30/09
Relevance Score: 64%
NK Cells, Autoantibodies, and Immunologic Infertility: A Complex Interplay
Clinical Reviews in Allergy and Immunology, 11/18/09
Relevance Score: 64%
Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to Disease Activity Score-28
Autoimmunity, 11/18/09
Relevance Score: 64%
Steroids' risks can equal their healing benefits
Internet Source, 11/16/09
Relevance Score: 64%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Micro-ribonucleic acid profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain, 12/04/09
Dysregulated Epstein-Barr virus infection in patients with CIDP
Journal of Neuroimmunology, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor